Member Info for Newuncle

However in the case of toffers I really do hope he ignores any symptoms and does not get tested, the end result would match his attitude to life and others.

I would like to think that by posting real research into Prostate Cancer screening etc we are actually increasing awareness to anyone reading it so they better appreciate the need and the benefits to real people of ensuring they have the knowledge to explore screening with their GPs or private health provider, regardless of whether it's the current PSA test or the more enhanced one from OBD.

Yes this is a public information channel as much as it is an investors channel.

Based on biomarker type, the pre-biopsy test in the U.S. prostate cancer testing market is expected to be dominated by the biomarker type segment. This is due to the increasing popularity of prostate cancer testing and rising awareness related to prostate cancer testing.

Based on application, the U.S. prostate cancer testing market is dominated by the diagnostics biomarkers segment owing to the rising R&D activity focused on the development of prostate cancer testing. The diagnosis of prostate cancer has developed a new molecular-based diagnostics technology. To detect clinically relevant cancer upon diagnosis, several tools or therapeutic options are required to improve the patient's quality of life.

The U.S. prostate cancer testing market is anticipated to reach $1,901.6 million in 2030 from $544.1 million in 2021, with a CAGR of 14.7%, during the forecast period 2022-2030.

The growth in the U.S. prostate cancer testing market is expected to be driven by high investments in the field of cancer research and the rising prevalence of prostate cancer in U.S. In addition, the focus of business leaders is establishing a deep understanding to address the unmet needs in clinical research to understand the prostate cancer market.

One of the main reasons for the expansion of the prostate cancer testing market in the upcoming years is the rise in prostate cancer cases. Prostate cancer is the second most frequent disease diagnosed in men, and its frequency is rising across the globe.

Prostate cancer is thought to be diagnosed in one million additional cases worldwide each year. Due to an aging population, growing urbanization, and accompanying lifestyle changes, the overall incidence of prostate cancer has increased over the past few decades.

Even a small improvement in screening could save lives, given that one in nine men in the United States will be diagnosed with prostate cancer and one in 40 will die from it, the researchers said.

In the USA

Prostate cancer rates rose by 3% a year between 2014 and 2019 after two decades of decline, and advanced prostate cancers increased by about 5% a year, the latest American Cancer Society statistics show.

The problem is that the signal delivered by current PSA screening — a man’s risk of prostate cancer — is too often mixed with background noise, the researchers explained.

Today, the initial step to diagnose prostate cancer is by testing PSA together with a digital rectal examination (DRE). The PSA test is a well-established prostate-specific marker that measures the concentration of PSA molecules (Prostate-Specific Antigen) in a blood sample. A high level of PSA can be a sign of prostate cancer. Therefore, clinical guidelines recommend a confirmatory prostate biopsy, if PSA > 3 ng/ml. But PSA levels can also be raised for many other reasons including infections, prostate stimulation, vigorous exercise or even certain medications. PSA results are confusing for many patients and even physicians. Patients are sent for time-consuming and anxiety-causing additional examinations, especially when a biopsy is being considered. Currently, over 50% of biopsies with elevated PSA are negative or clinically insignificant. This means overdiagnosis and overtreatment that impacts the physician's routine, our healthcare system, and the quality of patient's lives.

Patients with a PSA level between 2 and 10 ng/ml are in a diagnostic grey zone. In these cases, the doctor faces an inconclusive situation without having sufficient information to decide whether to continue investigating or discharge the patient. Unclear results cause patients anxiety and require both additional time spent on health care procedures and unnecessary biopsies.

Kenny,

Good luck and keep us posted please.

Ethiopia mine where no one has been in 30 years....no thanks

Congrats Simon, latest inductee to my personal hall of shame green boxes emporium, bye

Agreed guys, Bigger players have a horizon for investing beyond the next payday

I am very comfortable buying and holding here instead of getting spiked by P&D operators chasing a rainbow on a certain bombed out mining stock.

Don't sweat the small stuff, these girations are just bumps in the road imo

SJ agreed and confirms that too many rainbow chasers have zero patience to simply buy and hold.

Another one green boxed then, bye

Cheeky MMs BOT posted my sub 40p buy as a sell due to the spread.

c'est la vie, matters not a jot in reality.

Well i got more fwiw, MMs you can take it back up now.....

TIA

Well put Alf. Too easy to be distracted by others into panicking.

OBD have delivered a unique global offering, fully licenced and insurance approved in the USA.

Company have clearly shown how fast they can move through the processes for growth in securing USA insurance approvals in just 3 months instead of up to 2 years.

I fully expect that planning and delivery of expanded lab capacity will follow in short order to meet the high demand from clients following the official launch and insurance approvals.

100% fully committed here

O/T but I will only mention it once here, HZM bombing after being cross ramped here, LOFL and I know who they were and they are green boxed too.